Sugi Predict

Sugi Predict / Compounds / SCHEMBL719081

SCHEMBL719081

SCHEMBL719081

C=Cc1nc2ccccc2s1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 7/20 0.56
▸ RAB9A P51151 6/20 0.56
▸ NPC1 O15118 4/20 0.56
▸ L3MBTL1 Q9Y468 3/20 0.56
▸ CASP3 P42574 1/20 0.56
▸ SENP7 Q9BQF6 1/20 0.56
▸ MEN1 O00255 6/20 0.51
▸ KMT2A Q03164 6/20 0.51
▸ TDP1 Q9NUW8 2/20 0.51
▸ SMN1; SMN2 Q16637 2/20 0.49
▸ APP P05067 1/20 0.49
▸ INSR P06213 1/20 0.49
▸ NCOA1 Q15788 1/20 0.49
▸ ALDH1A1 P00352 4/20 0.48
▸ HPGD P15428 2/20 0.48
▸ ADRA2A P08913 1/20 0.48
▸ FBP1 P09467 1/20 0.48
▸ ADORA3 P0DMS8 1/20 0.48
▸ DRD2 P14416 1/20 0.48
▸ ALOX15 P16050 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL9634629 0.98 MAPT (0.54) MAPTRAB9ANPC1L3MBTL1CASP3
Iodide SCHEMBL8929776 0.98 MAPT (0.54) MAPTRAB9ANPC1L3MBTL1CASP3
Pyrene SCHEMBL28845423 0.91 MAPT (0.49) MAPTRAB9ANPC1L3MBTL1CASP3
SCHEMBL1306077 0.84 MAPT (0.49) MAPTRAB9ANPC1L3MBTL1CASP3
Nitrobenzene SCHEMBL28043005 0.83 MMP13 (0.56) MAPTRAB9ANPC1L3MBTL1CASP3
SCHEMBL6001350 0.81 MAPT (0.50) MAPTRAB9ANPC1L3MBTL1CASP3
SCHEMBL288476 0.81 MAPT (0.57) MAPTRAB9ANPC1L3MBTL1CASP3
SCHEMBL221982 0.79 PSMB8 (0.53) MAPTRAB9ANPC1L3MBTL1CASP3
SCHEMBL19844258 0.79 RAB9A (0.51) MAPTRAB9ANPC1L3MBTL1CASP3
SCHEMBL29954323 0.79 PSMB8 (0.53) MAPTRAB9ANPC1L3MBTL1CASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117756990-B Preparation process of low-smoke halogen-free flame-retardant environment-friendly electronic wire 东莞市中正电线电缆科技有限公司 2024-06-04 — — CN claimed
CN-117756990-A Preparation process of low-smoke halogen-free flame-retardant environment-friendly electronic wire 东莞市中正电线电缆科技有限公司 2024-03-26 — — CN claimed
CN-105713281-B Universal white master batch and preparation method thereof 上海宏盎实业发展有限公司 2017-12-12 — — CN claimed
CN-105713281-A Universal white master batch and preparation method thereof 上海宏盎实业发展有限公司 2016-06-29 — — CN claimed
US-20150202185-A1 COMPOSITIONS AND METHODS FOR TREATING LYSOSOMAL DISORDERS TAIJI BIOMEDICAL, INC. 2015-07-23 — — US claimed
US-20130012539-A1 Compositions and Methods for Treating Lysosomal Disorders THE HOSPITAL FOR SICK CHILDREN (CA) 2013-01-10 — — US claimed
EP-2211856-A1 COMPOSITIONS AND METHODS FOR TREATING LYSOSOMAL DISORDERS The Hospital For Sick Children (CA) 2010-08-04 — — EP claimed
EP-2082740-A2 Use of imidazole derivatives as MDR modulators Taiji Biomedical, Inc. (US) 2009-07-29 — — EP claimed
US-20090163500-A1 COMPOSITIONS AND METHODS FOR TREATING LYSOSOMAL DISORDERS THE HOSPITAL FOR SICK CHILDREN (CA) 2009-06-25 — — US claimed
WO-2009073564-A1 COMPOSITIONS AND METHODS FOR TREATING LYSOSOMAL DISORDERS THE HOSPITAL FOR SICK CHILDREN (CA) 2009-06-11 — — WO claimed
US-20070203215-A1 Methods & Compositions For Enhancing Pharmaceutical Treatments TAIJI BIOMEDICAL, INC. (US) 2007-08-30 — — US claimed
EP-0999835-A4 IMIDAZOLE DERIVATIVES AS MDR MODULATORS ONTOGEN CORP (US) 2004-08-25 — — EP claimed
US-20020147197-A1 Methods and compositions for enhancing pharmaceutical treatments TAIJI BIOMEDICAL, INC. 2002-10-10 — — US claimed
EP-0999835-A1 IMIDAZOLE DERIVATIVES AS MDR MODULATORS Ontogen Corporation (US) 2000-05-17 — — EP claimed
WO-1999002155-A1 IMIDAZOLE DERIVATIVES AS MDR MODULATORS ONTOGEN CORPORATION (US) 1999-01-21 — — WO claimed
US-12441823-B2 Resin composition for optical shaping KURARAY NORITAKE DENTAL INC. (JP) 2025-10-14 — — US disclosed
EP-4583709-A1 AQUEOUS ANTIMICROBIAL COMPOSITION Dow Global Technologies LLC (US) 2025-07-16 — — EP disclosed
US-4093570-A CROSSLINKABLE, MIXED ORGANIC MEDIUM; ASAHI KASEI KOGYO KABUSHIKI KAISHA (JA) 1978-06-06 — — US disclosed
US-4006127-A Cationic diazacyanine dyestuffs BAYER AKTIENGESELLSCHAFT (DT) 1977-02-01 — — US disclosed
US-3976640-A CYANINE POLAROID CORPORATION (US) 1976-08-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163500-A1 COMPOSITIONS AND METHODS FOR TREATING LYSOSOMAL DISORDERS GAA, GBA1, LIPA MAPT 691/4885RAB9A 252/4885NPC1 15/4885
US-20130012539-A1 Compositions and Methods for Treating Lysosomal Disorders GAA, GBA1, LIPA MAPT 691/4885RAB9A 252/4885NPC1 15/4885
US-20070203215-A1 Methods & Compositions For Enhancing Pharmaceutical Treatments TUBB3, TUBB1, TUBB2A MAPT 26/4885RAB9A 1628/4885NPC1 45/4885
US-20020147197-A1 Methods and compositions for enhancing pharmaceutical treatments TUBB3, TUBB1, TUBB2A MAPT 39/4885RAB9A 2063/4885NPC1 62/4885
US-20150202185-A1 COMPOSITIONS AND METHODS FOR TREATING LYSOSOMAL DISORDERS GAA, GBA1, LIPA MAPT 691/4885RAB9A 252/4885NPC1 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.